<div id="readability-page-1"><div><ul> <li>In recent days, Insperity’s partnership with Workday has been highlighted as potentially transformative, aiming to modernize its HR technology platform and expand into larger mid-market clients through the HRScale offering.</li> <li>This push to upgrade its technology stack and deepen client integration is being framed as a way to bolster retention and reinforce the resilience of Insperity’s outsourcing model despite recent earnings and analyst concerns.</li> <li>We’ll now examine how the Workday-enabled technology modernization could reshape Insperity’s existing investment narrative and long-term growth assumptions.</li> </ul><p>We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p><h2>Insperity Investment Narrative Recap</h2><p>To own Insperity, you need to believe that its HR outsourcing model can translate the Workday-enabled technology upgrade into better client retention and a larger, higher-value mid-market base, while eventually restoring earnings after recent profit pressure. In the near term, the key catalyst is clear execution on HRScale and the broader platform rollout, while the biggest risk is that elevated healthcare and benefits costs, alongside Workday investment spend, keep margins under strain despite the modernization story.</p> <p>Against this backdrop, Insperity’s steady quarterly dividend of US$0.60 per share through 2024 and 2025 stands out as the most relevant recent announcement, because it directly intersects with today’s margin and earnings pressure. Continued cash returns to shareholders, alongside rising healthcare costs and substantial Workday-related investment, tighten the margin for error if HRScale adoption or pricing actions take longer than expected to materially support profitability.</p> <p>Yet investors should also weigh how persistent healthcare cost inflation could interact with these higher platform investments and what that might mean for...</p> <p>Read the full narrative on Insperity (it's free!)</p><p>Insperity's narrative projects $7.7 billion revenue and $109.6 million earnings by 2028.</p><p>Uncover how Insperity's forecasts yield a $45.00 fair value, a 31% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/242f1389-7dfa-4be3-a46a-72a21ebf1222/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/242f1389-7dfa-4be3-a46a-72a21ebf1222/chart/quote-price"/><figcaption>NSP 1-Year Stock Price Chart</figcaption></figure> <p>Two fair value estimates from the Simply Wall St Community range from US$45 to US$176.78 per share, underscoring how far opinions can spread. You can set those views against the execution and cost risks tied to Insperity’s Workday partnership and decide which scenarios you think are most realistic.</p><p>Explore 2 other fair value estimates on Insperity - why the stock might be worth just $45.00!</p><h2>Build Your Own Insperity Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Insperity research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.</li><li>Our free Insperity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insperity's overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</li><li>The latest GPUs need a type of rare earth metal called Terbium and there are only 37 companies in the world exploring or producing it. Find the list for free.</li><li>AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Insperity's partnership with Workday aims to modernize its HR technology platform, targeting larger mid-market clients through HRScale. This modernization could enhance client retention and support Insperity's outsourcing model despite recent earnings pressures. Key risks include healthcare costs and Workday investment impacting margins. Insperity's steady dividend and revenue projections highlight its financial strategy. Fair value estimates for Insperity's stock vary widely, reflecting differing opinions on the partnership's impact. The article emphasizes independent analysis and does not constitute financial advice.</p>

Does Workday-Powered HRScale Modernization Change The Bull Case For Insperity (NSP)?